Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites

Commercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings ...

Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®

Members of the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) ...
Nasdaq

Microbot Medical Inc. Achieves Key Milestones in Preparation for LIBERTY® Endovascular Robotic System Launch

Microbot Medical Inc. announces key milestones, including FDA 510(k) submission, in preparation for LIBERTY's commercial launch in 2025. Microbot Medical Inc. announced the successful completion of ...
Nasdaq

Microbot Medical Inc. Strengthens U.S. Commercial Team with Key Executive Hires Ahead of LIBERTY® Launch

Microbot Medical Inc. has announced the addition of two senior executives to enhance its U.S. commercial leadership team in preparation for the upcoming launch of its LIBERTY® Endovascular Robotic ...

Microbot Medical Begins Full U.S. Launch of LIBERTY System

MBOT moves to full U.S. launch of its LIBERTY robotic system after strong hospital adoption, boosting momentum for faster market uptake and sales growth.